Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2025 to 2029
Are cures for cancer in sight? What is the opportunity in this market? What companies are poised to benefit? Is disruption a possibility? Find out in this comprehensive report.
A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR - T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon.
Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027.
All report data is available in Excel format on request.
Make investment decisions and valuations with confidence using the latest data.
Table of Contents
1. Market Guides
1.1. Situation Analysis
1.2. Guide for Executives and Marketing Staff
1.3. Guide for Investment Analysts and Management Consultants
2. Introduction and Market Definition
2.1. What is Cancer Immunotherapy?
2.2. Immunotherapy - the looming cures
2.3. Market Definition
2.3.1. Market Size
2.3.2. Currency
2.3.3. Years
2.4. Methodology
2.4.1. Methodology
2.4.2. Sources
2.4.3. Authors
2.5. U.S. Medical Market and Pharmceutical Spending - Perspective
2.5.1. Global Expenditures for Medicines
3. Immunotherapy - Guide to Immune Technologies
3.1. The Immune System
3.1.1. Innate immune system
3.1.1.1. Surface barriers
3.1.1.2. Inflammation
3.1.1.3. Complement system
3.1.1.4. Cellular barriers
3.1.1.5. Natural killer cells
3.1.2. Adaptive immune system
3.1.2.1. Lymphocytes
3.1.2.2. Killer T cells
3.1.2.3. Helper T cells
3.1.2.4. Gamma delta T cells
3.1.2.5. B lymphocytes and antibodies
3.1.3. Tumor immunology - the immune surveillance system
3.2. Immuno Oncology Technologies
3.2.1. Monoclonal Antibodies
3.2.1.1. Outlook for Monoclonal Antibodies
3.2.1.2. Companies with Monoclonal Antibodies in their Pipeline
3.2.2. Cancer vaccines
3.2.2.1. Outlook for Cancer Vaccines
3.2.2.2. Companies with Cancer Vaccines in their Pipeline
3.2.3. Cytokines
3.2.3.1. Outlook for Cytokines
3.2.3.2. Companies with Cytokines in their Pipeline
3.2.4. Cell Based Therapies
3.2.4.1. Outlook for Cell Based Therapies
3.2.4.2. Companies with Cell Based Therapies in their Pipeline
3.2.5. Inhibitors/Agonists
3.2.5.1. Outlook for Inhibitors/Agonists
3.2.5.2. Companies with Inhibitors/Agonists in their Pipeline
3.2.6. Antibody Drug Conjugates
3.2.6.1. Outlook for Antibody Drug Conjugates
3.2.6.2. Companies with Antibody Drug Conjugates in their Pipeline
3.2.7. Others
3.2.7.1. Outlook for Other Therapeutics
3.2.7.2. Companies with Viral Therapeutics in their Pipeline
3.2.7.3. Companies with Other Therapeutics in their Pipeline
4. Industry Overview
4.1. Market Players - Roles & Impacts
4.1.1. Drug manufacturers - Larger/pharmaceutical
4.1.2. Drug manufacturers - Generic
4.1.3. Contract Research and Manufacturing
4.1.4. In Vitro Diagnostics Industry
4.1.5. Drug Marketing Companies
4.1.6. Biotechnology Companies
4.1.7. Regulatory Bodies
5. Market Trends
5.1. Factors Driving Growth
5.1.1. Outcome potential
5.1.2. Fast tracking
5.1.3. Funding
5.1.4. Technology Environment
5.1.5. Target Solutions
5.2. Factors Limiting Growth
5.2.1. Cost of Treatment
5.2.2. Clinical Trials Role
5.2.3. Combinations
5.2.4. Protocols
5.3. Therapeutic Technology Development
5.3.1. Combinations - Issues and Complexity
5.3.2. Preference for a drug
5.3.3. Problems of Immunity Engineering
5.3.4. The Role of Cost
5.3.5. The Disruption Dynamic
5.3.6. CAR-T Cell Therapy
5.3.7. The Next Five Years
6. Cancer Immunotherapy Recent Developments
6.1. Recent Developments - Importance and How to Use This Section
6.1.1. Importance of These Developments
6.1.2. How to Use This Section
6.2. Merck, buys into new kind of cancer immunotherapy
6.3. Immunotherapy after surgery
6.4. Anti-CTLA-4 nanobody a promising approach
6.5. Continued Success with Immunotherapy in Melanoma
6.6. AC Immune Receives FDA Fast Track Designation
6.7. LTZ Announces Financing
6.8. Immunotherapy for Cancer Overview
6.9. Implantable device shrinks pancreatic tumors
6.10. mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence
6.11. Towards a Universal Cancer Immunotherapy
6.12. New Strategy May Improve T-Cell Therapy in Solid Tumors
6.13. Immunotherapy linked to increase in Medicare spending
6.14. Immunotherapy Effective with Ovarian Cancer
6.15. Cancer Immunotherapy Granted Fast Track
7. Profiles of Key Immunotherapy Companies
7.1. AbbVie
7.2. Achilles Therapeutics
7.3. Acumen Pharmaceuticals
7.4. Adagene
7.5. Adaptimmune Therapeutics
7.6. Adicet Bio
7.7. ALX Oncology Holdings
7.8. Ambrx Biopharma
7.9. Amgen
7.10. Apexigen
7.11. Arcus Biosciences
7.12. argenx
7.13. AstraZeneca
7.14. Atreca
7.15. Avalo Therapeutics
7.16. Avid Bioservices
7.17. Bavarian Nordic
7.18. BioAtla
7.19. Biogen Inc.
7.20. BioNTech
7.21. Bolt Biotherapeutics
7.22. Bristol-Myers Squibb
7.23. Candel Therapeutics
7.24. Caribou Biosciences
7.25. Celldex Therapeutics
7.26. Checkpoint Therapeutics
7.27. Chinook Therapeutics
7.28. Corvus Pharmaceuticals
7.29. Cullinan Oncology
7.30. Eli Lilly
7.31. EOM Pharmaceuticals
7.32. Evaxion Biotech
7.33. Genenta Science
7.34. Gilead Sciences
7.35. Gracell Biotechnologies
7.36. Greenwich LifeSciences
7.37. Gritstone bio
7.38. Harpoon Therapeutics
7.39. ImmunityBio
7.40. Immunocore Holdings
7.41. Immunome
7.42. IMV Inc
7.43. Incyte
7.44. Indaptus Therapeutics
7.45. Instil Bio
7.46. Iovance Biotherapeutics
7.47. Johnson & Johnson
7.48. Marker Therapeutics
7.49. Medicenna Therapeutics
7.50. Merck & Co.
7.51. Merus
7.52. Moderna
7.53. Mustang Bio
7.54. Nanobiotix
7.55. Neoleukin Therapeutics
7.56. Novartis
7.57. Novavax
7.58. Oncorus
7.59. PDS Biotechnology
7.60. Pfizer
7.61. Regeneron Pharmaceuticals
7.62. Roche
7.63. Sanofi
7.64. Sensei Biotherapeutics
7.65. Senti Biosciences
7.66. Surface Oncology
7.67. Takeda Pharmaceutical
7.68. TC Biopharm
7.69. ThermoGenesis Holdings
7.70. UroGen Pharma
7.71. Werewolf Therapeutics
7.72. Xilio Therapeutics
7.73. Zymeworks
8. The Global Market for Immuno-Oncology Therapeutics
8.1. Global Market Overview by Country
8.1.1. Table - Global Market by Country
8.1.2. Chart - Global Market by Country
8.2. Global Market by Therapy - Overview
8.2.1. Table - Global Market by Therapy
8.2.2. Chart - Global Market by Therapy - Base/Final Year Comparison
8.2.3. Chart - Global Market by Therapy - Base Year
8.2.4. Chart - Global Market by Therapy - End Year
8.2.5. Chart - Global Market by Therapy - Share by Year
8.2.6. Chart - Global Market by Therapy - Segments Growth
8.3. Global Market by Cancer - Overview
8.3.1. Table - Global Market by Cancer
8.3.2. Chart - Global Market by Cancer - Base/Final Year Comparison
8.3.3. Chart - Global Market by Cancer - Base Year
8.3.4. Chart - Global Market by Cancer - End Year
8.3.5. Chart - Global Market by Cancer - Share by Year
8.3.6. Chart - Global Market by Cancer - Segments Growth
8.4. Global Market by Customer - Overview
8.4.1. Table - Global Market by Customer
8.4.2. Chart - Global Market by Customer - Base/Final Year Comparison
8.4.3. Chart - Global Market by Customer - Base Year
8.4.4. Chart - Global Market by Customer - End Year
8.4.5. Chart - Global Market by Customer - Share by Year
8.4.6. Chart - Global Market by Customer - Segments Growth
9. Global Immuno-Oncology Therapy Markets - By Therapy
9.1. MAB
9.1.1. Table MAB - by Country
9.1.2. Chart - MAB Growth
9.2. Cytokine
9.2.1. Table Cytokine - by Country
9.2.2. Chart - Cytokine Growth
9.3. Vaccine
9.3.1. Table Vaccine - by Country
9.3.2. Chart - Vaccine Growth
9.4. Cell Based
9.4.1. Table Cell Based - by Country
9.4.2. Chart - Cell Based Growth
9.5. Inhibitor/Agonist
9.5.1. Table Inhibitor/Agonist - by Country
9.5.2. Chart - Inhibitor/Agonist Growth
9.6. Other IO Therapy
9.6.1. Table Other IO Therapy - by Country
9.6.2. Chart - Other IO Therapy Growth
10. Global Immuno-Oncology Therapeutic Markets - By Cancer
10.1. Breast
10.1.1. Table Breast - by Country
10.1.2. Chart - Breast Growth
10.2. ColoRectal
10.2.1. Table ColoRectal - by Country
10.2.2. Chart - ColoRectal Growth
10.3. Cervical
10.3.1. Table Cervical - by Country
10.3.2. Chart - Cervical Growth
10.4. Lung
10.4.1. Table Lung - by Country
10.4.2. Chart - Lung Growth
10.5. Precancer
10.5.1. Table Precancer - by Country
10.5.2. Chart - Precancer Growth
10.6. Prostate
10.6.1. Table Prostate - by Country
10.6.2. Chart - Prostate Growth
10.7. Melanoma
10.7.1. Table Melanoma - by Country
10.7.2. Chart - Melanoma Growth
10.8. Blood
10.8.1. Table Blood - by Country
10.8.2. Chart - Blood Growth
10.9. Other Cancer
10.9.1. Table Other Cancer - by Country
10.9.2. Chart - Other Cancer Growth
11. Global Immuno-Oncology Therapeutic Markets - By Customer